148 related articles for article (PubMed ID: 32827639)
1. Potential use of n-3 PUFAs to prevent oxidative stress-derived ototoxicity caused by platinum-based chemotherapy.
Cortés Fuentes IA; Burotto M; Retamal MA; Frelinghuysen M; Caglevic C; Gormaz JG
Free Radic Biol Med; 2020 Nov; 160():263-276. PubMed ID: 32827639
[TBL] [Abstract][Full Text] [Related]
2. The expression of copper transporters associated with the ototoxicity induced by platinum-based chemotherapeutic agents.
Perde-Schrepler M; Fischer-Fodor E; Virag P; Brie I; Cenariu M; Pop C; Valcan A; Gurzau E; Maniu A
Hear Res; 2020 Mar; 388():107893. PubMed ID: 32006874
[TBL] [Abstract][Full Text] [Related]
3. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
van As JW; van den Berg H; van Dalen EC
Cochrane Database Syst Rev; 2019 May; 5(5):CD009219. PubMed ID: 31063591
[TBL] [Abstract][Full Text] [Related]
4. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
van As JW; van den Berg H; van Dalen EC
Cochrane Database Syst Rev; 2014 Jul; (7):CD009219. PubMed ID: 24984156
[TBL] [Abstract][Full Text] [Related]
5. Incidence of platinum-induced ototoxicity in pediatric patients in Quebec.
Peleva E; Emami N; Alzahrani M; Bezdjian A; Gurberg J; Carret AS; Daniel SJ
Pediatr Blood Cancer; 2014 Nov; 61(11):2012-7. PubMed ID: 24976616
[TBL] [Abstract][Full Text] [Related]
6. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
van As JW; van den Berg H; van Dalen EC
Cochrane Database Syst Rev; 2012 May; (5):CD009219. PubMed ID: 22592737
[TBL] [Abstract][Full Text] [Related]
7. High accumulation of platinum-DNA adducts in strial marginal cells of the cochlea is an early event in cisplatin but not carboplatin ototoxicity.
Thomas JP; Lautermann J; Liedert B; Seiler F; Thomale J
Mol Pharmacol; 2006 Jul; 70(1):23-9. PubMed ID: 16569706
[TBL] [Abstract][Full Text] [Related]
8. Long-term auditory follow-up in the management of pediatric platinum-induced ototoxicity.
Fetoni AR; Brigato F; De Corso E; Lucidi D; Sergi B; Scarano E; Galli J; Ruggiero A
Eur Arch Otorhinolaryngol; 2022 Oct; 279(10):4677-4686. PubMed ID: 35024956
[TBL] [Abstract][Full Text] [Related]
9. Usefulness of current candidate genetic markers to identify childhood cancer patients at risk for platinum-induced ototoxicity: Results of the European PanCareLIFE cohort study.
Langer T; Clemens E; Broer L; Maier L; Uitterlinden AG; de Vries ACH; van Grotel M; Pluijm SFM; Binder H; Mayer B; von dem Knesebeck A; Byrne J; van Dulmen-den Broeder E; Crocco M; Grabow D; Kaatsch P; Kaiser M; Spix C; Kenborg L; Winther JF; Rechnitzer C; Hasle H; Kepak T; van der Kooi AF; Kremer LC; Kruseova J; Bielack S; Sorg B; Hecker-Nolting S; Kuehni CE; Ansari M; Kompis M; van der Pal H; Parfitt R; Deuster D; Matulat P; Tillmanns A; Tissing WJE; Beck JD; Elsner S; Am Zehnhoff-Dinnesen A; van den Heuvel-Eibrink MM; Zolk O;
Eur J Cancer; 2020 Oct; 138():212-224. PubMed ID: 32905960
[TBL] [Abstract][Full Text] [Related]
10. Platinum-induced ototoxicity in children: a consensus review on mechanisms, predisposition, and protection, including a new International Society of Pediatric Oncology Boston ototoxicity scale.
Brock PR; Knight KR; Freyer DR; Campbell KC; Steyger PS; Blakley BW; Rassekh SR; Chang KW; Fligor BJ; Rajput K; Sullivan M; Neuwelt EA
J Clin Oncol; 2012 Jul; 30(19):2408-17. PubMed ID: 22547603
[TBL] [Abstract][Full Text] [Related]
11. Evaluating protective and therapeutic effects of alpha-lipoic acid on cisplatin-induced ototoxicity.
Kim KH; Lee B; Kim YR; Kim MA; Ryu N; Jung DJ; Kim UK; Baek JI; Lee KY
Cell Death Dis; 2018 Aug; 9(8):827. PubMed ID: 30068942
[TBL] [Abstract][Full Text] [Related]
12. Incidence and associated risk factors for platinum-induced ototoxicity in pediatric patients.
Waissbluth S; Del Valle Á; Chuang A; Becker A
Int J Pediatr Otorhinolaryngol; 2018 Aug; 111():174-179. PubMed ID: 29958605
[TBL] [Abstract][Full Text] [Related]
13. C-phycocyanin from
Kim YR; Do JM; Kim KH; Stoica AR; Jo SW; Kim UK; Yoon HS
Mar Drugs; 2019 Apr; 17(4):. PubMed ID: 31010222
[TBL] [Abstract][Full Text] [Related]
14. Delayed administration of sodium thiosulfate in animal models reduces platinum ototoxicity without reduction of antitumor activity.
Muldoon LL; Pagel MA; Kroll RA; Brummett RE; Doolittle ND; Zuhowski EG; Egorin MJ; Neuwelt EA
Clin Cancer Res; 2000 Jan; 6(1):309-15. PubMed ID: 10656463
[TBL] [Abstract][Full Text] [Related]
15. Different infusion durations for preventing platinum-induced hearing loss in children with cancer.
van As JW; van den Berg H; van Dalen EC
Cochrane Database Syst Rev; 2016 Aug; (8):CD010885. PubMed ID: 27498707
[TBL] [Abstract][Full Text] [Related]
16. Different infusion durations for preventing platinum-induced hearing loss in children with cancer.
van As JW; van den Berg H; van Dalen EC
Cochrane Database Syst Rev; 2014 Jun; (6):CD010885. PubMed ID: 24968257
[TBL] [Abstract][Full Text] [Related]
17. Different infusion durations for preventing platinum-induced hearing loss in children with cancer.
van As JW; van den Berg H; van Dalen EC
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD010885. PubMed ID: 31961948
[TBL] [Abstract][Full Text] [Related]
18. Nrf2 activation protects auditory hair cells from cisplatin-induced ototoxicity independent on mitochondrial ROS production.
Zhang W; Xiong H; Pang J; Su Z; Lai L; Lin H; Jian B; He W; Yang H; Zheng Y
Toxicol Lett; 2020 Oct; 331():1-10. PubMed ID: 32428544
[TBL] [Abstract][Full Text] [Related]
19. Platinum-induced ototoxicity: a review of prevailing ototoxicity criteria.
Waissbluth S; Peleva E; Daniel SJ
Eur Arch Otorhinolaryngol; 2017 Mar; 274(3):1187-1196. PubMed ID: 27245751
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms of cisplatin-induced ototoxicity and prevention.
Rybak LP; Whitworth CA; Mukherjea D; Ramkumar V
Hear Res; 2007 Apr; 226(1-2):157-67. PubMed ID: 17113254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
